Financial Summary for Q1 FY2026 Ending September (Japan GAAP) (Consolidated)

Overview of Business Performance

Consolidated net sales for Q1 FY2026 ending September were JPY 15,897 million (22.3% YoY increase), primarily driven by steady performance of new drugs in the 'Women's Healthcare' segment. Operating income rose significantly to JPY 2,786 million (122.4% YoY increase), reflecting an increase in gross profit due to higher sales, which absorbed increased R&D expenses and depreciation costs. On the other hand, net income attributable to owners of parent decreased to JPY 324 million (67.2% YoY decrease), impacted by the recording of investment securities valuation losses.

Financial Position and Earnings Guidance

Total assets stood at JPY 95,080 million (an increase of JPY 1,675 million from the end of the previous period), and net assets were JPY 47,952 million (up JPY 1,044 million), with a stable equity ratio of 50.4%, maintaining a sound financial base. The number of shares issued was 24,891,100, with treasury shares totaling 421,339. The full-year earnings forecast for FY2026 ending September anticipates net sales of JPY 59,250 million (14.7% YoY increase), operating income of JPY 6,120 million (22.6% YoY increase), and net income attributable to owners of parent of JPY 2,240 million (25.3% YoY decrease).